Status:
NOT_YET_RECRUITING
Application of ⁶⁸Ga-FXX489 (NNS309) PET/CT Imaging in Diagnosis of Tumor Diseases.
Lead Sponsor:
Yi Tian
Conditions:
Tumor
Metastatic Cancer
Eligibility:
All Genders
18-80 years
Phase:
PHASE1
Brief Summary
A new radiotracer, 68Ga-FXX489 (NNS309), has been developed for tracking fibroblast activation protein (FAP) and visualizing the tumor stroma. The purpose of the study is to explore the diagnostic val...
Detailed Description
Initially the investigator(s) will focus on imaging pancreatic cancer, lung cancer, breast cancer, gastric cancer, colorectal cancer. STUDY AIMS 1. Determine the dosimetry for gallium-68 labelled 68...
Eligibility Criteria
Inclusion
- Patients with a high suspicion of oncological diseases.
- Age: 18-80 years, no gender restriction, able to express themselves independently, and willing to participate in this study with a signed informed consent form.
Exclusion
- Failure to sign the informed consent form.
- Severe visual or auditory impairment, cognitive disorders, or patients with claustrophobia who cannot communicate effectively.
- Severe cardiac dysfunction, cardiac function class III-IV.
- Renal failure (serum creatinine level \> 1.2 mg/dl).
- Allergy to alcohol.
- Use of drugs within 1 week prior to the examination that can cause a disulfiram-like reaction with alcohol, such as penicillins, cephalosporins, or cefotetan.
- Known pregnancy.
Key Trial Info
Start Date :
September 1 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2027
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT07144085
Start Date
September 1 2025
End Date
July 1 2027
Last Update
August 27 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The First Hospital of China Medical University
Shenyang, Liaoning, China, 110001